Navigation Links
JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells
Date:2/4/2008

NEW YORK, February 4, 2008 The Juvenile Diabetes Research Foundation (JDRF), the worlds largest charitable funder of type 1 diabetes research, announced today that it is partnering with Plureon Corporation, a biotechnology company based in Winston-Salem, N.C. that focuses on developing therapeutic applications of stem cells.

Through its Industry Discovery and Development Partnership Program, JDRF is providing $500,000 over two years of research funding aimed at developing an insulin-producing beta cell therapy product for the treatment of type 1 diabetes.

Plureon is exploring exciting alternatives to treat or cure diabetes by developing cell therapies to replace beta cells using adult stem cells as a source, said Julia Greenstein, Therapeutic Program Director for Replacement at JDRF. The results from this study may provide a new strategy to restore function of insulin-producing cells, creating a significant, positive clinical impact on patients with diabetes.

This award enables us to extend our research in the field of diabetes, said Hal Eason, founder and CEO of Plureon. By leveraging our existing technology and know-how across additional sources of stem cells, we hope to open new pathways towards a cure. We are grateful for JDRFs partnership in this pursuit.

The project plans to use Plureons technology platform to isolate adult stem cells from a type 1 diabetes patient and re-program them to generate fully functional pancreatic beta-cells. The objective is to return the re-programmed insulin-producing cells back into the patient in an autologous manner, i.e., without the need for immunosuppressive agents normally required for organ transplantation in this manner, the patients own transplanted cells will be capable of glucose-dependent insulin secretion and the restoration of normal blood sugar levels.

Plureon is the latest company to work with JDRF through its innovative Industry Discovery and Development Partnership program. Through the program, JDRF partners with pharmaceutical, biotech, and medical device businesses that seek to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications. To date, JDRF has 22 IDDP partners across a range of research areas, committing approximately $25 million in research funding.

Diabetes is a chronic, debilitating disease affecting every organ system. There are two major types of diabetes: type 1 and type 2. Type 1 diabetes is an autoimmune disease in which a persons pancreas stops producing insulin, a hormone that enables people to get energy from food. Type 1 diabetes usually strikes in childhood, adolescence, or young adulthood, but lasts a lifetime. People with type 1 diabetes must take multiple injections of insulin daily or continuous infusion of insulin through a pump just to survive. (Type 2 diabetes is a metabolic disorder in which a persons body still produces insulin but is unable to use it effectively.) Taking insulin does not cure any type of diabetes nor prevent the possibility of its eventual and devastating effects: kidney failure, blindness, nerve damage, amputation, heart attack, and stroke.


'/>"/>

Contact: Susan Sherman
ssherman@jdrf.org
212-479-7510
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related medicine news :

1. Sergeants(R) Pet Care Products Announces Cause Marketing Partnership With the National Wildlife Federation
2. Red Cross Partners with YeePay on China Snow Disaster Relief
3. Bobbi Brown Cosmetics Creates Limited-Edition Lip Palette in Partnership with The Heart Truths Red Dress Collection 2008 Fashion Show
4. HealthPartners Contracts with SEIU Healthcare Minnesota Expires with No Agreement on New Contracts
5. Bobbi Brown Cosmetics Creates Limited-Edition Red Lip Palette in Partnership With The Heart Truths 2008 Red Dress Collection
6. Helios Education Foundation Invests $6.5 Million in New Partnership with TGen
7. Abbey Spanier Rodd & Abrams, LLP Files Class Action Lawsuit on Behalf of Purchasers of American Dental Partners, Inc. Securities
8. MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers
9. Time Domain Adds Eleven Partners to its Channel Reseller Network of PLUS(TM) Ultra Wideband Solutions Providers
10. Arthur Patrick Partners Acquires Fit Fuel, LLC
11. Medical University of South Carolina (MUSC) and Halsey Institute Create Partnership Between Art and Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy ... prescription medications from over 180 American pharmaceutical companies for $35 per month, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... offering, the Protocol Calendar Exchange , is officially open to all sponsors ... calendars available for sites to download into their clinical trial management system (CTMS), ...
(Date:4/28/2016)... ... 2016 , ... On Thursday, April 14 orthopaedic surgeon ... Institute in Vail, Colorado, attended the American Academy of Orthopaedic Surgeons (AAOS) ... musculoskeletal disorders that are affecting millions of Americans today. Dr. LaPrade and many ...
(Date:4/28/2016)... Valley, California (PRWEB) , ... ... ... Inc. (AGNITY) a leading global provider of intelligent business communication applications and ... and go-live of its Number Portability solution at Bestel’s Communications Network. ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... CLEVELAND , April 26, 2016 ... is forecast to expand 4.9 percent annually to ... and other healthcare facilities to decrease rates of ... infection prevention supplies, equipment, and services.  Although declining, ... is significantly above targeted levels set by the ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
(Date:4/26/2016)... , April 26, 2016 ... Microbial identification Market Size, Share, Development, Growth ... Insights by Product (Consumables, Instruments and Software ... Genotypic Method), by Application (Diagnostic Application, Food ... Application) and by End User (Hospitals, Pharmaceutical ...
Breaking Medicine Technology: